Cara Therapeutics Financial Statements (CARA)

Cara Therapeuticssmart-lab.ru %   2020 2021 2022 2023 2023   LTM ?
Report date 25.02.2021 01.03.2022 06.03.2023 31.12.2023 06.03.2024   14.11.2024
Currency USD USD USD USD USD   USD
Financial report URL  
Revenue, bln rub ? 135.1 23.0 41.9 21.0 21.0   8.69
Operating Income, bln rub 5.39 -89.1 -87.5 -121.5 -121.5   -82.1
EBITDA, bln rub ? 5.59 -88.2 -83.8 -121.5 -117.7   -88.8
Net profit, bln rub ? 8.41 -88.2 -83.4 -118.5 -118.5   -95.5
OCF, bln rub ? -5.49 -60.1 -78.7 -92.1   -74.2
CAPEX, bln rub ? 0.349 0.039 0.043 2.38   3.10
FCF, bln rub ? -5.84 -60.1 -78.8 -94.5   -77.3
Dividend payout, bln rub 0.000 0.000 0.000 0.000   0.000
Ordinary share dividend yield, % 0.00% 0.00% 0.00% 0.00% 0.00%   0.00%
Dividend payout ratio, % 0.00% 0.00% 0.00% 0.00% 0.00%   0
OPEX, bln rub 129.7 112.1 122.1 136.3 142.5   90.5
Cost of production, bln rub 107.1 1.55 7.27 6.17 6.17   1.35
R&D, bln rub 107.9 82.7 91.9 108.5 108.5   61.0
Interest expenses, bln rub 0.000 0.000 0.000 0.604 0.604   6.46
Assets, bln rub 271.2 247.1 182.2 125.8 125.8   51.3
Net Assets, bln rub ? 249.0 227.5 158.8 57.1 57.1   0.707
Debt, bln rub 5.28 3.67 1.92 43.2 43.2   3.42
Cash, bln rub 180.9 167.0 145.4 100.8 100.8   42.0
Net debt, bln rub -175.7 -163.4 -143.5 -57.6 -57.6   -38.6
Ordinary share price, rub 15.1 12.2 10.7 0.743 0.743   1.18
Number of ordinary shares, mln 47.4 50.7 53.7 54.1 54.1   54.8
Market cap, bln rub 717 618 576 40 40   65
EV, bln rub ? 542 454 433 -17 -17   26
Book value, bln rub 249 228 159 57 57   1
EPS, rub ? 0.18 -1.74 -1.55 -2.19 -2.19   -1.74
FCF/share, rub -0.12 -1.19 -1.47 0.00 -1.74   -1.41
BV/share, rub 5.25 4.49 2.96 1.05 1.05   0.01
EBITDA margin, % ? 4.14% -383.0% -200.2% -579.4% -561.1%   -1 022%
Net margin, % ? 6.23% -383.0% -199.2% -565.2% -565.2%   -1 100%
FCF yield, % ? -0.81% -9.73% -13.7% 0.00% -234.8%   -119.5%
ROE, % ? 3.38% -38.8% -52.5% -207.6% -207.6%   -13 511%
ROA, % ? 3.10% -35.7% -45.8% -94.2% -94.2%   -186.1%
P/E ? 85.3 -7.00 -6.91 -0.34 -0.34   -0.68
P/FCF -122.9 -10.3 -7.32 -0.43   -0.84
P/S ? 5.31 26.8 13.8 1.92 1.92   7.45
P/BV ? 2.88 2.72 3.63 0.70 0.70   91.5
EV/EBITDA ? 96.8 -5.15 -5.16 0.14 0.15   -0.29
Debt/EBITDA -31.4 1.85 1.71 0.47 0.49   0.43
R&D/CAPEX, % 30 903% 212 054% 213 672% 4 569%   1 969%
CAPEX/Revenue, % 0.26% 0.17% 0.10% 0.00% 11.3%   35.7%
Cara Therapeutics shareholders